```html

Cavernous Sinus Thrombosis (CST)

Overview

Cavernous sinus thrombosis (CST) is a rare, life‑threatening condition in which a blood clot forms inside the cavernous sinus—a large venous channel located at the base of the skull behind each eye. The clot blocks normal blood flow, leading to inflammation, infection spread, and potential damage to the cranial nerves and eye structures that travel through the sinus.

• Typical age group: Adults 20–50 years old, but it can affect children and the elderly.
• Gender: Slight male predominance (≈55 % of cases), likely reflecting higher rates of sinus infections in men.
• Prevalence: Approximately 1–2 cases per 1 million people per year in the United States; still considered an uncommon disorder (Mayo Clinic).
• Why it matters: Without rapid treatment, mortality can exceed 30 % and survivors often have permanent ocular or neurologic deficits.

Symptoms

Symptoms usually develop rapidly—often within 24‑48 hours—owing to the acute nature of the clot and any underlying infection. The classic presentation is “triad” of:

• Severe periorbital (around the eye) pain
• Proptosis (bulging of the eye)
• Ophthalmoplegia (paralysis of the eye muscles) causing double vision

Because the cavernous sinus contains several cranial nerves (III, IV, V1, V2, VI), a wide array of signs can appear:

Eye‑related signs

• Ptosis: Drooping upper eyelid due to CN III involvement.
• Diplopia: Double vision from impaired extra‑ocular muscles.
• Reduced pupil reflex: Dilated or non‑reactive pupil (CN III).
• Conjunctival chemosis: Swelling of the eye’s surface.
• Vision loss: Rare, usually from optic nerve compression.

Neurologic signs

• Facial numbness or hypoesthesia in the distribution of V1 (forehead) and V2 (cheek).
• Headache—often severe, unilateral, and worse when lying down.
• Fever and chills if the clot is septic.
• Altered mental status or seizures in advanced cases (due to spread of infection to the brain).

Systemic signs

• Fever ≥ 38 °C (100.4 °F)
• General malaise, fatigue
• Elevated white blood cell count

Causes and Risk Factors

CST can be septic (most common) or aseptic (non‑infectious). The underlying mechanisms differ:

Septic (infectious) CST

• Facial or sinus infections: Acute bacterial sinusitis, especially of the sphenoid or ethmoid sinuses.
• Dental infections: Periapical abscesses of the maxillary teeth.
• Skull‑base trauma: Penetrating injuries that introduce bacteria.
• Ophthalmic procedures: Orbital surgery, endoscopic sinus surgery, or even facial cosmetic injections.
• Skin infections: Severe facial cellulitis, especially in immunocompromised hosts.

Aseptic (non‑infectious) CST

• Hypercoagulable states (e.g., factor V Leiden, antiphospholipid syndrome, cancer‑associated thrombosis).
• Pregnancy and the postpartum period (increased clotting factors).
• Use of oral contraceptives or hormone replacement therapy.
• Systemic inflammatory diseases (e.g., vasculitis, Behçet’s disease).
• Trauma or surgery that damages venous endothelium without infection.

Who is at higher risk?

• Adults with chronic sinus disease or recurrent facial infections.
• Individuals with impaired immunity (HIV, chemotherapy, long‑term steroids).
• Patients with known clotting disorders or who are on estrogen‑containing medications.
• People who have recently undergone facial or neurosurgical procedures.

Diagnosis

Because CST can progress in hours, a high index of suspicion is essential. Diagnosis combines clinical assessment with urgent imaging and laboratory work.

Clinical assessment

• Focused neurologic exam (cranial nerves III–VI and V1/V2).
• Evaluation of eye movements, pupil size/reactivity, and facial sensation.

Imaging studies

• Magnetic Resonance Venography (MRV): Gold standard; shows filling defects in the cavernous sinus.
• Contrast‑enhanced MRI: Detects inflammation, abscess, or extension to adjacent structures.
• CT Venography (CTV): Faster, widely available; useful in emergency settings.
• Standard CT with contrast: May reveal sinus opacification or bony erosion in septic cases.

Laboratory tests

• Complete blood count (CBC) – leukocytosis if infection present.
• Blood cultures – essential for septic CST; positive in 30–50 % of cases.
• Coagulation profile – PT/INR, aPTT, D‑dimer (elevated in thrombosis).
• Hypercoagulable work‑up (if aseptic): protein C/S, antithrombin III, factor V Leiden, antiphospholipid antibodies.

Other considerations

Lumbar puncture is generally avoided unless meningitis is strongly suspected, as it can worsen intracranial pressure.

Treatment Options

Management requires a multidisciplinary team (neurology, infectious disease, ophthalmology, otolaryngology, and interventional radiology). The goals are to eradicate infection, restore venous flow, and prevent permanent neurologic damage.

1. Antimicrobial therapy (septic CST)

• Empiric broad‑spectrum IV antibiotics started immediately – typically a combination of:
  • Vancomycin (covers MRSA)
  • Ceftriaxone or Cefotaxime (gram‑negative rods)
  • Metronidazole (anaerobes)
• Tailor to culture results within 48‑72 h.
• Duration: 3–4 weeks of IV therapy, followed by oral antibiotics if infection resolves.
• Reference: CDC Antibiotic Guidelines.

2. Anticoagulation (both septic and aseptic)

• Heparin (unfractionated or low‑molecular‑weight) is initiated promptly unless there is active bleeding.
• Goal: therapeutic aPTT (for UFH) or anti‑Xa level (for LMWH).
• Transition to oral anticoagulants (warfarin with INR 2–3, or DOACs) for 3–6 months in aseptic cases; longer if underlying hypercoagulable disorder persists.
• Evidence: A systematic review in Brain (2020) found mortality reduction from 30 % to ≈15 % with anticoagulation, without a significant rise in intracranial hemorrhage.

3. Interventional procedures

• Endovascular thrombolysis or mechanical thrombectomy: Reserved for patients who deteriorate despite anticoagulation or have extensive clot burden.
• Surgical drainage: Indicated when a paranasal sinus or orbital abscess is identified and can be accessed safely.

4. Supportive care

• Analgesia for severe periorbital pain (acetaminophen, short‑course opioids if needed).
• Control of fever (antipyretics).
• Elevated head of bed to reduce venous congestion.

5. Lifestyle and adjunct measures

• Hydration to maintain adequate blood viscosity.
• Smoking cessation – smoking increases clot risk.
• Management of underlying conditions (e.g., diabetes control, sinus disease treatment).

Living with Cavernous Sinus Thrombosis

Even after acute treatment, many patients experience lingering symptoms. The following strategies help maximise recovery and quality of life:

• Follow‑up imaging: Repeat MRV at 4‑6 weeks to confirm recanalisation.
• Vision & eye‑movement therapy: Referral to an ophthalmologist and a strabismus specialist for prisms or eye‑muscle surgery if diplopia persists.
• Neurologic rehabilitation: Physical therapy for facial weakness or balance issues.
• Medication adherence: Complete the full course of antibiotics and anticoagulants as prescribed.
• Monitoring for recurrence: Promptly report new headaches, eye pain, or visual changes.
• Psychological support: Anxiety and depression are common after severe infections; counseling or support groups can be beneficial.

Prevention

Because many cases stem from infections, preventing sinus and facial infections is the most effective strategy.

• Prompt treatment of acute sinusitis, dental abscesses, or facial cellulitis.
• Good oral hygiene; regular dental check‑ups.
• Avoidance of nasal or facial trauma; use protective gear when appropriate.
• Vaccinations that lower risk of upper‑respiratory infections (influenza, COVID‑19).
• For patients with known hypercoagulable disorders:
  • Regular review of anticoagulation therapy.
  • Consider low‑dose aspirin or prophylactic LMWH during high‑risk periods (e.g., postpartum).
• Limit prolonged use of estrogen‑containing medications if you have additional clot risk factors; discuss alternatives with your provider.

Complications

If left untreated or if treatment is delayed, CST can cause serious, sometimes irreversible, damage:

• Vision loss: From optic nerve ischemia or retinal vein occlusion.
• Permanent ophthalmoplegia: Persistent double vision or eye‑movement restriction.
• Cranial nerve palsies: Facial numbness, loss of corneal reflex.
• Intracranial extension: Meningitis, cerebral abscess, or venous infarction.
• Septic emboli: Spread of infection to lungs or other organs.
• Long‑term thrombotic tendency: Higher risk of recurrent venous thromboses.
• Mortality: Historically 30–50 % before modern antibiotics; modern series report 10–20 % mortality despite aggressive therapy (CDC).

When to Seek Emergency Care

Early recognition and treatment dramatically improve outcomes. If you suspect cavernous sinus thrombosis, do not wait—seek medical attention right away.

```